NASDAQ:ABMD
Delisted
ABIOMED Stock News
$381.02
+0 (+0%)
At Close: Mar 20, 2023
There are a lot more losing than winning stocks in the S&P 500, Jim Cramer says
10:28pm, Thursday, 20'th Aug 2020
"We have a bizarre situation where some companies are doing very well" while "a lot of other companies are getting crushed," the "Mad Money" host said.
GRAPHIC-Big Tech drives S&P 500 to record high in coronavirus rally
04:45pm, Tuesday, 18'th Aug 2020
The S&P 500 hit a record high on Tuesday, thanks largely to months of outperformance from Amazon and other heavyweight technology companies viewed by investors as likely to emerge from the coronavirus
ABIOMED (NASDAQ:ABMD) Price Target Raised to $217.00
10:50am, Tuesday, 11'th Aug 2020
ABIOMED (NASDAQ:ABMD) had its price target hoisted by Morgan Stanley from $152.00 to $217.00 in a report issued on Friday, BenzingaRatingsTable reports. They currently have an underweight rating on th
Impella心臓ポンプ、米国食品医薬品局（FDA）からCOVID-19患者の心臓負荷軽減治療に緊急使用許可を取得
12:00am, Tuesday, 11'th Aug 2020
（ビジネスワイヤ） -- 米国食品医薬品局（FDA）は、ECMO治療中で肺水腫または心筋炎を発症したCOVID-19患者に左心室の負荷軽減と循環補助をするため�
After 150 days of the COVID-19 pandemic, here are the best- and worst-performing stocks
11:06am, Monday, 10'th Aug 2020
The tech sector is still in the lead, but consumer-discretionary group trails only slightly.
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abiomed (ABMD –
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q1
01:26pm, Thursday, 06'th Aug 2020
ABIOMED's (ABMD) flagship Impella saw decline in revenues internationally and within the United States, in Q1.
Abiomed (ABMD) Tops Q1 Earnings and Revenue Estimates
12:25pm, Thursday, 06'th Aug 2020
Abiomed (ABMD) delivered earnings and revenue surprises of 176.19% and 19.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Abiomed Announces Q1 FY 2021 Revenue of $165 Million and 21% Operating Margin | | IT Business Net
12:02pm, Thursday, 06'th Aug 2020
June Revenue Up 4% Versus Prior Year DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported first quarter fiscal 20
Abiomed Announces Q1 FY 2021 Revenue of $165 Million and 21% Operating Margin
11:00am, Thursday, 06'th Aug 2020
Abiomed announces Q1 FY 2021 revenue of $165 million and 21% operating margin.
La Food and Drug Administration (FDA) américaine vient d'octroyer une autorisation d'utilisation d'urgence (EUA) aux pompes cardiaques Impella pour of
La Administración de Alimentos y Medicamentos de Estados Unidos (Food and Drug Administration, FDA) ha emitido una autorización de uso de emergencia (
Stocks close higher as stimulus talks continue, with Nasdaq notching new high
08:10pm, Tuesday, 04'th Aug 2020
Stocks closed modestly higher after a choppy trading session Tuesday, with investors keeping one eye on stimulus talks in Washington and another on mixed...
Abiomed’s Impella Scores Emergency FDA Nod For Covid-19 Patients
04:39pm, Tuesday, 04'th Aug 2020
Abiomed (ABMD) has announced that the US Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart
